P2X purinoceptor 7 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14P2X purinoceptor 7 shows clinical signal disease relevance led by rheumatoid arthritis. 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q99572. Start with rheumatoid arthritis, then reuse UniProt Q99572 as the stable protein anchor across project notes and exports.
Start with rheumatoid arthritis, then reuse UniProt Q99572 as the stable protein anchor across project notes and exports.
P2X purinoceptor 7 shows clinical signal disease relevance led by rheumatoid arthritis. 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include AZD9056, CE-224535. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyP2X purinoceptor 7
Review this target as P2X purinoceptor 7, mapped to UniProt Q99572. Sequence length is 595 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats P2X purinoceptor 7 as ChEMBL target CHEMBL4805, mapped to UniProt Q99572. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether P2X purinoceptor 7 is the right protein anchor across sources, using UniProt Q99572 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why rheumatoid arthritis is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | P2X purinoceptor 7 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q99572 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | P2X purinoceptor 7 |
| UniProt Accession | Q99572 |
| Component Type | Protein |
| Sequence Length | 595 aa |
P2X purinoceptor 7
Review this target as P2X purinoceptor 7, mapped to UniProt Q99572. Sequence length is 595 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
P2X purinoceptor 7 shows clinical signal disease relevance led by rheumatoid arthritis. 3 more disease programs remain visible in the same review block.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include AZD9056, CE-224535. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2324343 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL550030 | 10.3 | IC50 | 0.05012 | Preclinical |
| CHEMBL3415305 | 10.22 | IC50 | 0.06 | Preclinical |
| CHEMBL560506 | 10.1 | IC50 | 0.07943 | Preclinical |
| CHEMBL3679059 | 10.05 | IC50 | 0.09 | Preclinical |
| CHEMBL4165149 | 9.96 | IC50 | 0.11 | Preclinical |
| CHEMBL5430904 | 9.82 | IC50 | 0.15 | Preclinical |
| CHEMBL3663243 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL3663257 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL551360 | 9.7 | IC50 | 0.1995 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 190 | 1,997 | 7.2 |
| single protein format | 52 | 1,081 | 7.2 |
| assay format | 24 | 2,139 | 7.3 |
| tissue-based format | 5 | 19 | 7.2 |
| cell membrane format | 2 | 10 | 7.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 59 | 508 | 7.0 |
| assay format | 14 | 212 | 7.0 |
| tissue-based format | 2 | 35 | 6.8 |